Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 2:2:RRN1175.
doi: 10.1371/currents.RRN1175.

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic

Grace Wang  1 , Robin K Kelley, Gappnet
Affiliations

KRAS mutational analysis for colorectal cancer. Application: pharmacogenomic

Grace Wang et al. PLoS Curr. .

Abstract

KRAS mutational analysis is a genetic test used in clinical practice for determining the status of the KRAS gene (wild type or mutant) in tumors from patients with metastatic colorectal cancer (CRC). Persons whose tumors are wild type may respond to therapies cetuximab (Erbitux) or panitumumab (Vectibix).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Normanno, N., et al., Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol, 2009. 6(9): p. 519-27. - PubMed
    1. KRAS mutations and epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer. Technol Eval Cent Asses Program Exec Summ, 2009. 23(6): p. 1-3. - PubMed
    1. National Cancer Institute. SEER Stat Fact Sheets: Colon and Rectum. 2010 [cited 2010 April 26];http://seer.cancer.gov/statfacts/html/colorect.html
    1. NCCN Updates Guidelines for Colorectal Cancer ; NCCN announces new updates to the NCCN Guidelines for Colon and Rectal Cancers . The updates include recommendations to the pre-treatment work-up and use of anti- cancer agents in patients with metastatic colorectal cancer depending on the status of the tumor's KRAS gene. The changes are based on recent studies demonstrating that the tumor KRAS gene status is highly predictive of outcome with certain therapies, in Business Wire. 2008.
    1. National Comprehensive Cancer Network. Colon Cancer. NCCN Clinical Practice Guidelines in Oncology 2009 [cited 2009 October 21];http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf